Efficacy and Tolerance of Cellularised LG002 Versus Uncellularised LG002 in the Treatment of Severe Burns Injuries

NCT00366041 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

20

Enrollment

INDUSTRY

Sponsor class

Stopped not appropriate to carry on the study

Conditions

Burns

Interventions

DRUG: Dermal substrate cellularised LG002 (10x10cm)
DEVICE: Dermal substrate uncellularised LG002 (10x10 cm)

Sponsor

Laboratoires Genévrier

Collaborators

[object Object]
[object Object]